Gut Microbes and Eye Disease

Patrick Donabedian^a Elizabeth Dawson^a Qihong Li^b Jinghua Chen^b

^aCollege of Medicine, University of Florida, Gainesville, FL, USA; ^bDepartment of Ophthalmology, University of Florida, Gainesville, FL, USA

Keywords

Gut microbiome · Glaucoma · Age-related macular degeneration · Diabetic retinopathy · Autoimmune uveitis

Abstract

Microbial symbionts in the gut are increasingly recognized as having important effects on health and disease, but have only recently begun to be linked to diseases of the eye. We review current research on the intestinal microbiota's relationship to ocular disease, focusing on autoimmune uveitis, diabetic retinopathy, age-related macular degeneration, and primary-open angle glaucoma. We discuss findings and limitations of this exciting new area of ophthalmology research and explore possible future disease-modifying treatments.

© 2021 The Author(s).

Published by S. Karger AG, Basel

Introduction

The human gut microbiota comprises an estimated 4×10^{13} bacteria [1] and other microorganisms [2] which play important reciprocally regulated roles in host digestion and absorption [3], immune function [4, 5], vitamin and amino acid synthesis [6], and drug metabolism [7, 8]. Dysbiosis of the gut has well-supported ties to a host of human diseases, including cardiovascular disease [9, 10],

metabolic syndrome and diabetes [11, 12], gastrointestinal and systemic autoimmune disease [13], and cancer, as well as chronic and inflammatory diseases of the eye [14]. Until recently, the effects of microbiota on ophthalmic disease have been less studied than gastrointestinal and systemic diseases. While there is ample research on the relationship between microbiota and systemic conditions (for example, high blood pressure and diabetes) which affect the incidence and progression of eye disease, clinical and basic research on ocular disease specifically has accelerated only in the last few years. Recent evidence aimed at elucidating the relationship between the human eye and gut microbiota supports the presence of a gut-eye axis, i.e., effects of gut microorganism-derived mediators on structures within the eye (Fig. 1) [15, 16]. In support of the gut-eye axis, many studies have uncovered an association between alterations in gut microbial composition and ocular disease, as well as possible therapeutic effects of manipulating the microbiome with dietary interventions and antibiotic treatment. This review will focus on gut microbiota and intraocular diseases; we will review current research on association of gut microbiota with autoimmune uveitis, diabetic retinopathy (DR), age-related macular degeneration (AMD), and primary open-angle glaucoma (POAG).

Patrick Donabedian and Elizabeth Dawson contributed equally.

Fig. 1. Downstream direct and indirect effects of gut dysbiosis on the eye. Maladaptive changes in the microbial communities overlying oral/intestinal mucosa may be induced by diet, environmental exposures, illness, or drugs, causing diverse effects on eye physiology.

Autoimmune Uveitis

Uveitis is a disease characterized by inflammation of the uvea, a structure in the eye composed of the choroid, iris, and ciliary body, as well as the neural retina; clinical manifestations vary with the involved anatomy but include redness, pain, photophobia, and loss of visual acuity. Uveitis affects 115.3 per 100,000 people in the USA, with a similar lifetime incidence worldwide, and is reportedly more common in females than in males [17, 18]. Inflammation in uveitis can be triggered through either noninfectious or infectious mechanisms, though this article will focus on noninfectious or autoimmune uveitis due to its well-studied relationship to gut microbial dysbiosis. Autoimmune uveitis may be isolated or associated with a wide range of systemic inflammatory conditions; it is a clinically and mechanistically heterogeneous group of diseases. We will discuss the association between gut microbial composition and uveitis and then review the hypothetical mechanisms by which gut dysbiosis may contribute to intraocular inflammation.

In studies on human fecal samples, gut microbial diversity was decreased in the uveitis condition; one study found differences in within-group (alpha) diversity [19], while another found differences in between-group (beta) diversity [20]. Principal component analysis of 16S rRNA sequences of gut microbes in uveitis patients and healthy controls found significantly divergent bacterial communities. Closer analysis of microbial composition found decreased abundance of the genera *Ruminococcus* and *Oscillospora* in uveitis patients [20], while another study did not find a significant difference in gut microbiota composition between uveitis patients and controls [19]. In one study, the genera *Faecalibacterium*, *Bacteroides*, *Clostridium*, and *Lachnospira*, which are known for their anti-inflammatory properties, were found to be reduced in uveitis patients and *Prevotella*, a pro-inflammatory genus, to be enriched [20]. These studies were unable to ascertain if observed changes in gut microbial composition were responsible for or a result of disease. Interestingly, gas chromatography-mass spectrometry analysis of fecal samples from anterior acute uveitis patients yielded a significant difference in fecal metabolic phenotype com-

pared to healthy controls [19]. These results suggest that even if changes in microbial composition are undetectable or inconsistent, there could be functional differences in the guts of uveitis patients contributing to disease.

The results of these studies, as well as an extensive literature on associations between gut microbiota and systemic autoimmune diseases linked to uveitis [13], raise the question of the mechanism by which gut bacteria may affect the eye. There are 4 proposed mechanisms implicating gut microbial dysbiosis in the pathogenesis of autoimmune uveitis. These mechanisms are microbial metabolites, destruction of the intestinal barrier, imbalance of intestinal immune homeostasis, and antigenic mimicry [21]. In the first hypothesized mechanism, microbes in the gut are capable of producing a number of metabolites, including butyric acid and short-chain fatty acids, which have protective properties in inflammation. Alterations in the microbial composition of the gut can decrease levels of beneficial microbial metabolites, exacerbating inflammation in uveitis. In the second mechanism, a weakened intestinal barrier due to dysbiosis can lead to leakage of pathogenic products of microbes into the systemic circulation. These products such as lipopolysaccharides could land in the uvea and elicit an immune response, leading to uveitis [22]. In the third mechanism, an imbalance of T helper 17 (Th17) and T regulatory cells results in overproduction of IL-17, stimulating an inflammatory pathway and promoting uveitis [23, 24]. The last mechanism involves antigenic mimicry whereby T cells capable of recognizing self-antigens in the uvea are activated in the gut by microbial peptides. One study found that T cells activated by an experimental autoimmune mouse model's intestinal extracts induced autoimmune uveitis in naïve wild-type mice, supporting antigenic mimicry as an inciting role in autoimmune uveitis [25]. It is likely that more than one of these hypothesized mechanisms are at play in the pathogenesis of autoimmune uveitis as they are not mutually exclusive and reflect a complex interplay of immune cells and gut microbial dysbiosis.

Diabetic Retinopathy

DR is one of the cardinal manifestations of microvascular compromise in diabetes mellitus. DR is divided into nonproliferative DR, proliferative DR, and diabetic macular edema. Retinal changes associated with uncontrolled diabetes are typically asymptomatic for years until late stages, when visual compromise may progress rapidly due to vitreous hemorrhage, tractional detachment, sec-

ondary glaucoma, or macular edema. For this reason and because of the high prevalence of diabetes, DR is the leading cause of blindness among working adults in developed countries and is associated with significant health-care costs [26–28]. Duration and severity of hyperglycemia as well as high blood pressure are the primary risk factors for development and progression of DR, but patient-specific factors also exist – some people never develop DR despite years of hyperglycemia. Many studies have demonstrated effects of gut microbiota on diabetes [12], but relatively few have investigated effects specifically on DR. In this section, we will discuss experimental evidence investigating the relationship between the gut microbiota and DR.

Several studies have investigated the differences in gut microbial composition between diabetic patients with and without DR; the first, using traditional selective culture media techniques, found no significant differences [29], while the second, using 16S rRNA gene sequencing from 25 patients with diabetes, 28 patients with DR, and 30 age- and sex-matched healthy controls [30], found differences at the genus level, with DR patients' stool having reduced abundance of both anti-inflammatory and pathogenic genera. More than half of patients in the diabetes cohort of this study had a new (<4 months) diagnosis, whereas the DR patients all had years-long history of diabetes. Treatment with metformin, for example, has been shown to have predictable effects on the gut microbiome that may form part of its mechanism of action [31]. In an effort to determine if DR-associated microbiota changes exist independently of those induced by years of diabetes or its treatment, Khan et al. [32] performed 16S rRNA sequencing on fecal swabs from 37 patients with sight-threatening DR and 21 matched controls, all with greater than 10 years' history of diabetes; they found no significant differences in abundance of measured taxa, though the ratio of Bacteroidetes to Firmicutes was found to be significantly different between patients and controls. In a similar vein, Huang et al. [33] evaluated 25 patients with DR, 25 patients with T2DM without DR matched for duration of disease, and 25 healthy controls. Significant differences were found between healthy controls and the DM and DR groups, but few differences were found between DM and DR groups. More research is needed to validate these results and determine if gut microbiota affect DR independent of DM status.

In animal models, several studies have discovered a relationship between a favorable gut microbial environment and improved DR outcomes in diabetic rodent models [34, 35]. Intermittent fasting (IF) was found to

both induce a shift from bacterial species of Bacteroidetes to Firmicutes in the gut, to decrease the activation of retinal microglia and infiltration of peripheral immune cells into the retina, and to improve overall survival in a type 2 diabetic mouse model [34]. Species belonging to Firmicutes can metabolize primary bile acids to secondary bile acids such as tauroursodeoxycholic acid (TUDCA), a compound found to have protective properties in rat retinal neurons [35, 36]. The authors hypothesized that an increased proportion of Firmicutes in the gut could improve DR outcomes through the protective effects of TUDCA, a byproduct of Firmicutes bile acid metabolism. The mechanism by which TUDCA improves DR outcomes was explored in experiments on rat retinas exposed to a diabetic condition [35–37]. TUDCA was found to decrease expression of immune mediators and angiogenic factors such as nitric oxide synthase, ICAM-1, NF- κ B p65, and VEGF in diabetic mouse models. In cultured rat retinal neurons exposed to elevated glucose concentrations, TUDCA decreased cell death by attenuating the release of apoptosis-inducing factor in mitochondria and reducing oxidative damage [35]. TGR5, a receptor of TUDCA, has been shown to play a role in DR pathology in mouse models [38]. These results suggest that TUDCA may play a number of roles in preventing DR progression such as alleviating inflammation and preventing retinal cell death in DR.

Overall, these studies also propose that dietary modifications such as IF and administration of TUDCA could be used as treatments for DR and other retinal diseases. IF was found to shift the gut microbial community towards larger proportions of *Firmicutes*, thus increasing bile acid metabolism and TUDCA production [34]. Future research points towards elucidating a more specific gut microbial profile associated with DR and tailoring treatments of retinal diseases involving TUDCA [39].

Age-Related Macular Degeneration

AMD, the leading cause of adult blindness in high-income countries, is a multifactorial disease with incompletely understood pathogenesis, but epidemiologic studies have implicated genetic differences, innate immunity [40, 41], inflammatory markers [42], diet [43, 44], and specific vitamin [45] intake in AMD incidence and progression. Given that microbiota shape both host immune response and metabolism [46, 47], and that diet shapes gut microbial communities [48], recently researchers have sought to find effects of microbiota on AMD. Two

case-control studies from the same group found that the feces of AMD patients were enriched in bacterial taxa associated with high-fat diet and inflammation, such as *Anaerotruncus*, and reduced in *Bacteroides* spp., which are associated with protection from autoimmune disease and fermentation of indigestible carbohydrates [49, 50]. The authors found associations between the complement system and gut microbiome changes in C3^{-/-} mice – a genetic background that negatively affects aged retinas – including increases in Firmicutes-to-Bacteroidetes ratio and the abundance of order Clostridiales. In humans, similar gut microbiome changes were correlated with single nucleotide polymorphisms in the complement factor H gene, suggesting a relationship between complement deficiency, specific gut microbiome changes, and AMD. Metabolic pathway inferences suggested that gut bacteria of AMD patients have reduced fatty acid elongation and increased L-alanine fermentation, glutamate degradation, and arginine biosynthesis, which may plausibly affect retinal health [51, 52]. Corroborating these studies, Andriessen and coworkers found that wild-type mice fed a high-fat diet have both greater choroidal neovascularization in response to experimental laser injury and an increased ratio of gut bacteria in phylum Firmicutes at the expense of Bacteroidetes, as well as increased gut dye permeability and measures of systemic and choroidal inflammation [53]. Normalization of gut bacterial phyla via fecal transplant restored normal-diet levels of laser-induced choroidal neovascularization, regardless of diet, indicating that gut microbiota are a necessary intermediary for diet-induced increases in choroidal angiogenesis. Rowan et al. [54] found that mice fed a high-glycemic-index diet develop features similar to dry AMD, including retinal pigmented epithelium depigmentation and atrophy, as well as changes in gut bacteria. As in prior studies, both the high-glycemic-index diet and worse retinal pathology were associated with increased abundance of phylum Firmicutes (including Clostridia) and reduced abundance of phylum Bacteroidetes; the authors identified reduced bacteria-derived serotonin as a diet-independent factor in retinal damage [54]. It is challenging to generalize to human disease from animal models of AMD since only the primate eye has a macula [55], but these results suggest that a shift in gut microbes may be a factor in AMD pathogenesis. Mechanisms may include increased systemic inflammation by permeation of antigens through a compromised intestinal mucosal barrier, bacterial metabolism of lipids or neurotransmitters, or bioavailability of dietary vitamins or micronutrients. This work merits further validation in human patients with AMD.

Finally, a role for oral dysbiosis in AMD has also been investigated in 2 case-control studies. In a cohort of 311 mixed AMD patients and 421 healthy controls in Singapore, Ho et al. [56] found that pharyngeal microbiota were similar in overall structure and diversity between AMD and control patients, with differences in the abundance of specific genera. *Prevotella* spp. was found to be relatively reduced, and *Gemella* and *Streptococcus* spp. relatively enriched, in AMD; this difference was found to be larger and *Leptotrichia* spp. also reduced when stratifying for late AMD. *Prevotella* spp. being less common in AMD is surprising, since members of genus cause periodontal disease [57] and are associated with autoimmune arthritis [58]. In a small case-control study of oral and nasal microbiota, Rullo et al. [59] found large differences in many taxonomic units of bacteria, including some linked to atherosclerosis, and recapitulated the prior study's finding of enrichment of *Gemella* spp. in AMD. Both studies suffered from a lack of baseline matching between the AMD and control cohorts. More work needs to be done to establish a role for oral or nasal microbiota in AMD.

In summary, multiple studies in mice and humans have identified changes in gut bacteria, specifically an increased fecal Firmicutes:Bacteroidetes ratio, as a possible factor in both neovascular and dry AMD. More work needs to be done to validate these findings in wider groups of patients and to elucidate whether these changes are a diet-dependent. Studies of oral microbiota in AMD have not produced convincing evidence of an association.

Glaucoma

Glaucoma is a group of neurodegenerative diseases of the optic nerve head associated with increased intraocular pressure (IOP); together they are the world's leading cause of irreversible blindness. Many theories have been promulgated to explain the observed patterns of neurodegeneration in patients with glaucoma and their relationship with elevated IOP, but none have prevailed. Since autoantibodies to retinal [60] and optic nerve antigens [61] were discovered in glaucoma patients in the 1990s, autoimmunity has been hypothesized to play various roles (including protective ones) in glaucomatous neurodegeneration. In addition to circulating antibodies, abnormal T-cell repertoires have been identified in glaucoma patients [62]. Recently, work on the effects of microbiota on the intraocular pathology of glaucoma has accelerated, often focused on autoimmune or inflamma-

tory aspects. Some of this work on glaucoma has been reviewed previously [14, 63–65], and may be divided into studies of oral microbiota and studies of gut microbiota, including gastric *H. pylori* colonization and gut microbiota-mediated autoimmunity to heat shock proteins (HSPs). The one study that does not fit into these categories, interestingly, performed stool 16S RNA sequencing and serum GC-MS metabolomics to explore differences in microbiota-mediated metabolism in 30 POAG and 30-matched controls [66]. The authors found that stool samples of POAG patients were relatively enriched in *E. coli* and Prevotellaceae and relatively reduced in *Bacteroides plebeius* and *Megamonas* spp. and linked these taxa to specific metabolites that may play a role in glaucoma pathogenesis.

Based on a well-tread hypothesis that innate or adaptive immune response to the oral biofilm may mediate neurodegenerative changes [67], as well as evidence of a role for both complement cascade [68] and the TLR4 receptor [69, 70] in glaucoma, several authors have pursued a link between oral microbiota and glaucoma. Promising initial results [70] of almost 2-fold differences in oral bacterial counts in POAG patients versus matched controls were not replicated in a prospective follow-up study [71]. Prospective data from the Health Professionals Follow-up Study [72] and a large retrospective cohort study in Taiwan [73] found inconsistent connections between oral health and risk of glaucoma, with the former study finding that only recent tooth loss alone or tooth loss and periodontal disease was associated with POAG, while the second study found that only periodontal disease was associated with POAG. The link between oral health and glaucoma remains unclear.

Glaucoma was first associated with gut microbiota in 2000, when histologically confirmed gastric *H. pylori* infection was found in 88% of glaucoma patients versus 47% of anemic controls by Kountouras et al. [74]. Subsequent studies using serology and/or (¹³C)urea breath testing found mixed results [75], but the most recent meta-analyses overall found evidence of an association between active *H. pylori* infection and POAG [76, 77]. *H. pylori* infection has been hypothesized to worsen glaucoma via systemic inflammation and increased vasoactive and reactive oxygen species [69] or antibody-dependent responses to cross-reactive ocular antigens [78]. One study even found *H. pylori* coccoid forms in trabecular and iris specimens from POAG patients [79], a surprising but likely artifactual finding given that *H. pylori* is an obligate colonizer of gastric mucosa [80]. Successful eradication of *H. pylori* infection in small trials of POAG patients has

been found to improve both IOP [81] and visual fields [82], but eradication in patients with peptic ulcer disease without glaucoma, however, did not change the risk of developing POAG [83]. There remains insufficient evidence to determine if a causative relationship exists, or if the observed association arises from shared susceptibility; subsequent studies on gut microbiota in POAG have taken the observed association with *H. pylori* infection as an indication that intestinal dysbiosis is a risk factor for both diseases [65].

The third and final line of investigation into microbiota and glaucoma concerns gut microbiota-mediated immune responses to HSPs, which are a large family of molecular chaperones that play diverse roles in signaling and stress response. Autoantibodies to small HSPs were identified in the serum of patients with POAG in 1998 [84], quickly followed by attempts to determine their role in glaucoma pathogenesis [85, 86]. HSPs are both immunogenic and highly conserved, and loss of tolerance to commensal bacterial HSP homologs has been proposed to contribute to many autoimmune and neurodegenerative diseases [87]. In 2018, Chen et al. [88] provided compelling evidence for this model, showing that transient IOP elevation in mice causes HSP-specific T-cells to infiltrate the retina and contribute to RGC and axon loss, and that this process is attenuated in a low-diversity gnotobiotic mouse model and abolished in germ-free mice [88]. They then generated a germ-free version of the DBA/2J mouse model of hereditary glaucoma and found that while those animals developed the expected elevation in IOP, they had no RGC and minimal axon loss by 12 months of age. Furthermore, the authors identified HSP-reactive T-cells in the peripheral blood of glaucomatous patients but not healthy patients or those with other diseases. The authors integrated these findings into a two-hit model of glaucoma pathogenesis: first, exposure to commensal bacteria in some way primes a T-cell response against self-antigens; second, elevated IOP (or another insult) allows T-cell infiltration into the retina and stimulates retinal cells to express stress factors that become the target of a sustained immune response that drives neurodegeneration and vision loss. These striking results raise several questions. First, *Rag1*^{-/-} and *TCRβ*^{-/-} mice subjected to transient IOP elevation still developed RGC and axon loss, while otherwise immunocompetent GF mice did not, indicating that classical αβ T-cell responses are not responsible for the bulk of neurodegeneration. Second, the timing and nature of immune priming by gut microbiota, or how they may differ between individuals with glaucoma, remains unknown. More work remains to be done to eluci-

date other roles for microbiota in glaucoma and to characterize differences in microbiota among patients with glaucomatous disease.

In summary, a real association exists between POAG and active *H. pylori* infection, but it remains unclear if eradication provides any ocular benefit. Evidence in mice indicates that intestinal dysbiosis may contribute to glaucoma progression by inducing immune intolerance to cross-reactive retinal antigens, but these findings will need to be corroborated in humans. Small observational studies have found inconsistent associations between POAG and periodontal disease.

Concluding Remarks

Many of these studies have significant limitations. Because gut and other microbiota are sensitive to diet, environment, and other aspects of the life history, observational studies cannot control for all possible confounders. Studies may be inadvertently using gut microbiota as a proxy for socioeconomic status, diet quality, or environmental exposures. A standardized approach has been proposed, using parallel clinical and translational research in both patients and germ-free mice, to better establish causality in microbiota research [46]. Successful trials are also a nice way to establish causation, but interventions to modify gut flora lag behind the techniques used to characterize them in sophistication and subtlety (see Table 1). Probiotics and prebiotics have mixed evidence of efficacy [89, 90] and are difficult to standardize. Heterologous fecal microbiota transplantation has strong evidence of efficacy in certain conditions (e.g., recurrent *Clostridoides difficile* infection) [91], but is even harder to standardize, with high variance in outcomes based on donor stool quality [92]. Administration of antibiotics in the absence of specific pathogens can only reduce diversity and is not safe. On the horizon are several emerging methods that may provide new ways to leverage discoveries about microbial symbionts in disease. Administering postbiotics, i.e., microbe-derived products rather than the live organism, may avoid bioavailability issues and be easier to standardize; this approach was discussed above in the context of DR. Microbial strains have been engineered both to efficiently colonize the gut and to express disease-modifying pathways [93]. Finally, bacteriophage therapy [94] or CRISPR-Cas9-based methods [95] may allow the microbiome to be edited in situ without needing to introduce new species.

Now research on gut microbiota and ocular health faces an exciting prospect. Many connections have been un-

Table 1. Interventions proposed to alter gut microbes for disease modification

Intervention	Strengths	Limitations
Antibiotics [46]	Effective in suppressing susceptible organisms	Unlikely to promote the growth of desirable organisms, reduces diversity, contributes to antimicrobial resistance
Probiotics/prebiotics [89, 90]	Widely used, safe	Most preparations fail to colonize the intestines, hard to standardize
Fecal microbiota transplantation [91, 92]	Proven effective in some conditions	Donor-dependent, resource intensive
"Postbiotics" (bacterial products) [35, 36, 46]	Easier to standardize	Unclear efficacy
Engineered bacterial strains [93]	Possibly more reliable colonization, controllable	Complex, untested
Phage/CRISPR-Cas9 modification [94, 95]	Targeted introduction or ablation of specific genes or pathways in situ	Complex, untested

covered between gut microbiota and several chronic eye diseases, but much work remains to be done to elucidate these connections with increasing specificity and certainty. Most importantly, prospective studies need to determine if intervening on gut dysbiosis has a meaningful effect on the prognosis of ocular diseases. Some of these mechanisms may prove to be the foundation of new treatments, and basic and clinical research will need to evolve together to realize the potential of these discoveries in this rapidly changing field.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

References

- Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. *Cell*. 2016 Jan; 164(3):337–40.
- Matijašić M, Meštrović T, Čipčić Paljetak H, Perić M, Barešić A, Verbanac D. Gut microbiota beyond bacteria – mycobiome, virome, archaeome, and eukaryotic parasites in IBD. *Int J Mol Sci*. 2020 Apr;21(8):2668.
- Cani PD, Van Hul M, Lefort C, Depommier C, Rastelli M, Everard A. Microbial regulation of organismal energy homeostasis. *Nat Metab*. 2019 Jan;1(1):34–46.
- Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. *Cell Res*. 2020 Jun;30(6):492–506.
- Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. *Science*. 2016 Apr;352(6285):539–44.
- Hacquard S, Garrido-Oter R, González A, Spaepen S, Ackermann G, Lebeis S, et al. Microbiota and host nutrition across plant and animal kingdoms. *Cell Host Microbe*. 2015 May;17(5):603–16.
- Dave M, Higgins PD, Middha S, Rioux KP. The human gut microbiome: current knowledge, challenges, and future directions. *Transl Res*. 2012 Oct;160(4):246–57.
- Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem J*. 2017 Jun; 474(11):1823–36.
- Zhao D, Cho J, Kim MH, Guallar E. The association of blood pressure and primary open-angle glaucoma: a meta-analysis. *Am J Ophthalmol*. 2014 Sep;158(3):615–27.e9.
- Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. *Hypertension*. 2015 Jun;65(6):1331–40.
- Zhao D, Cho J, Kim MH, Friedman DS, Guallar E. Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. *Ophthalmology*. 2015 Jan;122(1):72–8.
- Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. *EBioMedicine*. 2020 Jan;51:102590.

Funding Sources

Funding was provided in part by NIH Grants EY021752, EY024564, and American Diabetes Association grants to Q.L., and NIH P30 EY02172 and Research to Prevent Blindness grants to the University of Florida. Funders had no role in study design or manuscript preparation.

Author Contributions

P.D. and E.D. performed the literature review and wrote the paper. J.C. and Q.L. designed the study and edited the paper. All authors approved the final version of the manuscript.

- 13 Dehner C, Fine R, Kriegel MA. The microbiome in systemic autoimmune disease: mechanistic insights from recent studies. *Curr Opin Rheumatol*. 2019 Mar;31(2):201–7.
- 14 Cavuto KM, Banerjee S, Galor A. Relationship between the microbiome and ocular health. *Ocul Surf*. 2019 Jul;17(3):384–92.
- 15 Floyd JL, Grant MB. The gut-eye axis: lessons learned from murine models. *Ophthalmol Ther*. 2020 Sep;9(3):499–513.
- 16 Rowan S, Taylor A. The role of microbiota in retinal disease. In: Ash J, Anderson R, LaVail M, Bowes Rickman C, Hollyfield J, Grimm C, editors. *The role of microbiota in retinal disease*: Springer, Cham; 2018. p. 429–35.
- 17 Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Kalogeropoulos C, et al. A focus on the epidemiology of uveitis. *Ocul Immunol Inflamm*. 2018 Jan;26(1):2–16.
- 18 Amador-Patarroyo M, Cristina Peñaranda A, Teresa Bernal M. Autoimmune uveitis. In: Anaya J, Shoenfeld Y, Rojas-Villarraga A, editors. *Autoimmunity: from bench to bedside [Internet]*. Bogota, Columbia: El Rosario University Press; 2013.
- 19 Huang X, Ye Z, Cao Q, Su G, Wang Q, Deng J, et al. Gut microbiota composition and fecal metabolic phenotype in patients with acute anterior uveitis. *Investig Ophthalmology Vis Sci*. 2018 Mar;59(3):1523.
- 20 Kalyana Chakravarthy S, Jayasudha R, Sai Prashanthi G, Ali MH, Sharma S, Tyagi M, et al. Dysbiosis in the gut bacterial microbiome of patients with uveitis, an inflammatory disease of the eye. *Indian J Microbiol*. 2018 Dec; 58(4):457–69.
- 21 Fu X, Chen Y, Chen D. The role of gut microbiome in autoimmune uveitis. *Ophthalmic Res*. 2021;64(2):168–77.
- 22 Rosenbaum JT, Asquith M. The microbiome and HLA-B27-associated acute anterior uveitis. *Nat Rev Rheumatol*. 2018 Dec;14(12): 704–13.
- 23 Nakamura YK, Metea C, Karstens L, Asquith M, Gruner H, Moscirocki C, et al. Gut microbial alterations associated with protection from autoimmune uveitis. *Investig Ophthalmology Vis Sci*. 2016 Jul;57(8):3747.
- 24 Zhuang Z, Wang Y, Zhu G, Gu Y, Mao L, Hong M, et al. Imbalance of Th17/Treg cells in pathogenesis of patients with human leukocyte antigen B27 associated acute anterior uveitis. *Sci Rep*. 2017 Mar;7(1):40414.
- 25 Horai R, Zárate-Bladés CR, Dillenburg-Pilla P, Chen J, Kielczewski JL, Silver PB, et al. Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site. *Immunity*. 2015 Aug;43(2):343–53.
- 26 Leasher JL, Bourne RRA, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. *Diabetes Care*. 2016 Sep;39(9):1643–9.
- 27 Zhang X, Saaddine JB, Chou C-F, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. *JAMA*. 2010 Aug;304(6):649.
- 28 Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, et al. The economic burden of major adult visual disorders in the United States. *Arch Ophthalmol*. 2006 Dec;124(12): 1754.
- 29 Moubayed NM, Bhat RS, Al Farraj D, Dihani NA, El Ansary A, Fahmy RM. Screening and identification of gut anaerobes (Bacteroidetes) from human diabetic stool samples with and without retinopathy in comparison to control subjects. *Microb Pathog*. 2019 Apr; 129:88–92.
- 30 Das T, Jayasudha R, Chakravarthy S, Prashanthi GS, Bhargava A, Tyagi M, et al. Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy. *Sci Rep*. 2021 Dec;11(1):2738.
- 31 Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature*. 2015 Dec;528(7581):262–6.
- 32 Khan R, Sharma A, Ravikumar R, Parekh A, Srinivasan R, George RJ, et al. Association Between Gut Microbial Abundance and Sight-Threatening Diabetic Retinopathy. *Invest Ophthalmol Vis Sci*. 1552–5783. 2021;62(7): 19.
- 33 Huang Y, Wang Z, Ma H, Ji S, Chen Z, Cui Z, et al. Dysbiosis and implication of the gut microbiota in diabetic retinopathy. *Front Cell Infect Microbiol*. 2021 Mar;11:646348.
- 34 Beli E, Yan Y, Moldovan L, Vieira CP, Gao R, Duan Y, et al. Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice. *Diabetes*. 2018 Sep;67(9):1867–79.
- 35 Wang C, Yuan J, Qin D, Gu J, Zhao B, Zhang L, et al. Protection of tauroursodeoxycholic acid on high glucose-induced human retinal microvascular endothelial cells dysfunction and streptozotocin-induced diabetic retinopathy rats. *J Ethnopharmacol*. 2016 Jun;185: 162–70.
- 36 Gaspar JM, Martins A, Cruz R, Rodrigues CM, Ambrósio AF, Santiago AR. Tauroursodeoxycholic acid protects retinal neural cells from cell death induced by prolonged exposure to elevated glucose. *Neuroscience*. 2013 Dec;253:380–8.
- 37 Oshitari T, Bikbova G, Yamamoto S. Increased expression of phosphorylated c-Jun and phosphorylated c-Jun N-terminal kinase associated with neuronal cell death in diabetic and high glucose exposed rat retinas. *Brain Res Bull*. 2014 Feb;101:18–25.
- 38 Zhu L, Wang W, Xie T, Zou J, Nie X, Wang X, et al. TGR5 receptor activation attenuates diabetic retinopathy through suppression of RhoA/ROCK signaling. *FASEB J*. 2020 Mar; 34(3):4189–203.
- 39 Fernández-Sánchez L, Bravo-Osuna I, Lax P, Arranz-Romera A, Maneu V, Esteban-Pérez S, et al. Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats. *PLoS One*. 2017 May;12(5): e0177998.
- 40 Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. *Science*. 2005 Apr;308(5720):385–9.
- 41 Lee AY, Kulkarni M, Fang AM, Edelstein S, Osborn MP, Brantley MA. The effect of genetic variants in SERPING1 on the risk of neovascular age-related macular degeneration. *Br J Ophthalmol*. 2010 Jul;94(7):915–7.
- 42 Boekhoorn SS. C-reactive protein level and risk of aging macula disorder. *Arch Ophthalmol*. 2007 Oct;125(10):1396.
- 43 Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. *JAMA*. 1994 Nov; 272(18):1413–20.
- 44 SanGiovanni JP, Chew EY, Clemons TE, Davis MD, Ferris FL, Gensler GR, et al. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. *Arch Ophthalmol*. 2007 May;125(5):671–9.
- 45 Watstein DM, McEnerney MP, Styczynski MP. Precise metabolic engineering of carotenoid biosynthesis in *Escherichia coli* towards a low-cost biosensor. *Metab Eng*. 2015;31: 171–80.
- 46 Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nat Rev Microbiol*. 2021 Jan;19(1):55–71.
- 47 Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. *N Engl J Med*. 2016 Dec;375(24):2369–79.
- 48 David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature*. 2014 Jan;505(7484): 559–63.
- 49 Zinkernagel MS, Zysset-Burri DC, Keller I, Berger LE, Leichtle AB, Largiadèr CR, et al. Association of the intestinal microbiome with the development of neovascular age-related macular degeneration. *Sci Rep*. 2017;7(1):40826.
- 50 Zysset-Burri DC, Keller I, Berger LE, Largiadèr CR, Wittwer M, Wolf S, et al. Associations of the intestinal microbiome with the complement system in neovascular age-related macular degeneration. *NPJ Genomic Med*. 2020 Dec;5(1):34.
- 51 Liu A, Chang J, Lin Y, Shen Z, Bernstein PS. Long-chain and very long-chain polyunsaturated fatty acids in ocular aging and age-related macular degeneration. *J Lipid Res*. 2010 Nov;51(11):3217–29.
- 52 Bui BV, Hu RG, Acosta ML, Donaldson P, Vingrys AJ, Kalloniatis M. Glutamate metabolic pathways and retinal function. *J Neurochem*. 2009 Oct;111(2):589–99.

- 53 Andriessen EM, Wilson AM, Mawambo G, De-jda A, Miloudi K, Sennlaub F, et al. Gut microbiota influences pathological angiogenesis in obesity-driven choroidal neovascularization. *EMBO Mol Med*. 2016 Dec;8(12):1366–79.
- 54 Rowan S, Jiang S, Korem T, Szymanski J, Chang M-L, Szelog J, et al. Involvement of a gut-retina axis in protection against dietary glycemia-induced age-related macular degeneration. *Proc Natl Acad Sci U S A*. 2017 May;114(22):E4472–81.
- 55 Pennesi ME, Neuringer M, Courtney RJ. Animal models of age related macular degeneration. *Mol Aspects Med*. 2012 Aug;33(4):487–509.
- 56 Ho EXP, Cheung CMG, Sim S, Chu CW, Wilm A, Lin CB, et al. Human pharyngeal microbiota in age-related macular degeneration. *PLoS One*. 2018 Aug;13(8):e0201768.
- 57 Potempa M, Potempa J, Kantyka T, Nguyen K-A, Wawrzonek K, Manandhar SP, et al. Interpain A, a cysteine proteinase from *Prevotella intermedia*, inhibits complement by degrading complement factor C3. *PLoS Pathog*. 2009 Feb;5(2):e1000316.
- 58 Scher JU, Szczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion of intestinal *Prevotella copri* correlates with enhanced susceptibility to arthritis. *Elife*. 2013 Nov;2:e01202.
- 59 Rullo J, Far PM, Quinn M, Sharma N, Bae S, Irrcher I, et al. Local oral and nasal microbiome diversity in age-related macular degeneration. *Sci Rep*. 2020 Dec;10(1):3862.
- 60 Romano C, Barrett DA, Li Z, Pestronk A, Wax MB. Anti-rhodopsin antibodies in sera from patients with normal-pressure glaucoma. *Invest Ophthalmol Vis Sci*. 1995 Sep;36(10):1968–75.
- 61 Tezel G, Edward DP, Wax MB. Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. *Arch Ophthalmol*. 1999;117(7):917–24.
- 62 Yang J, Patil RV, Yu H, Gordon M, Wax MB. T cell subsets and sIL-2R/IL-2 levels in patients with glaucoma. *Am J Ophthalmol*. 2001 Apr;131(4):421–6.
- 63 Nayyar A, Gindina S, Barron A, Hu Y, Danias J. Do epigenetic changes caused by commensal microbiota contribute to development of ocular disease? A review of evidence. *Hum Genomics*. 2020 Dec;14(1):11.
- 64 Baim AD, Movahedan A, Farooq AV, Skon-dra D. The microbiome and ophthalmic disease. *Exp Biol Med*. 2019 Apr;244(6):419–29.
- 65 Henein C, Khaw PT. The interplay between inflammation, immunity and commensal microflora in glaucomatous neurodegeneration. *Ann Eye Sci*. 2019 Mar;4:10.
- 66 Gong H, Zhang S, Li Q, Zuo C, Gao X, Zheng B, et al. Gut microbiota compositional profile and serum metabolic phenotype in patients with primary open-angle glaucoma. *Exp Eye Res*. 2020 Feb;191:107921.
- 67 Cicciù M. Neurodegenerative disorders and periodontal disease: is there a logical connection? *Neuroepidemiology*. 2016;47(2):94–5.
- 68 Hubens WHG, Mohren RJC, Liesenborghs I, Eijssen LMT, Ramdas WD, Webers CAB, et al. The aqueous humor proteome of primary open angle glaucoma: an extensive review. *Exp Eye Res*. 2020 Aug;197:108077.
- 69 Shibuya E, Meguro A, Ota M, Kashiwagi K, Mabuchi F, Iijima H, et al. Association of Toll-like receptor 4 gene polymorphisms with normal tension glaucoma. *Investig Ophthalmology Vis Sci*. 2008 Oct;49(10):4453.
- 70 Astafurov K, Elhawy E, Ren L, Dong CQ, Igboin C, Hyman L, et al. Oral microbiome link to neurodegeneration in glaucoma. *PLoS One*. 2014 Sep;9(9):e104416.
- 71 Polla D, Astafurov K, Hawy E, Hyman L, Hou W, Danias J. A pilot study to evaluate the oral microbiome and dental health in primary open-angle glaucoma. *J Glaucoma*. 2017 Apr;26(4):320–7.
- 72 Pasquale LR, Hyman L, Wiggs JL, Rosner BA, Joshupura K, McEvoy M, et al. Prospective study of oral health and risk of primary open-angle glaucoma in men. *Ophthalmology*. 2016 Nov;123(11):2318–27.
- 73 Sun K-T, Shen T-C, Chen S-C, Chang C-L, Li C, Li X, et al. Periodontitis and the subsequent risk of glaucoma: results from the real-world practice. *Sci Rep*. 2020 Dec;10(1):17568.
- 74 Kountouras J, Mylopoulos N, Boura P, Bessas C, Chatzopoulos D, Venizelos J, et al. Relationship between *Helicobacter pylori* infection and glaucoma. *Ophthalmology*. 2001 Mar;108(3):599–604.
- 75 Zullo A, Ridola L, Hassan C, Bruzzese V, Papini F, Vaira D. Glaucoma and *Helicobacter pylori*: eyes wide shut? *Dig Liver Dis*. 2012 Aug;44(8):627–8.
- 76 Zeng J, Liu H, Liu X, Ding C. The relationship between *Helicobacter pylori* infection and open-angle glaucoma: a meta-analysis. *Invest Ophthalmol Vis Sci*. 2015 Aug;56(9):5238.
- 77 Douleris M, Papaefthymiou A, Polyzos SA, Bargiotas P, Liatsos C, Srivastava DS, et al. Association between active *Helicobacter pylori* infection and glaucoma: a systematic review and meta-analysis. *Microorganisms*. 2020 Jun;8(6):894.
- 78 Kountouras J, Mylopoulos N, Konstas AG, Zavos C, Chatzopoulos D, Boukla A. Increased levels of *Helicobacter pylori* IgG antibodies in aqueous humor of patients with primary open-angle and exfoliation glaucoma. *Graefes Arch Clin Exp Ophthalmol*. 2003 Nov;241(11):884–90.
- 79 Zavos C, Kountouras J, Sakkias G, Venizelos I, Deretzi G, Arapoglou S. Histological presence of *Helicobacter pylori* bacteria in the trabeculum and iris of patients with primary open-angle glaucoma. *Ophthalmic Res*. 2012;47(3):150–6.
- 80 Logan RP. Adherence of *Helicobacter pylori*. *Aliment Pharmacol Ther*. 1996 Apr;10 Suppl 1:3–15.
- 81 Ala S, Maleki I, Sanjari Araghi A, Sahebna-sagh A, Shahraki A. *Helicobacter pylori* eradication in the management of glaucoma. *Caspian J Intern Med*. 2020;11(2):143–9.
- 82 Kountouras J, Mylopoulos N, Chatzopoulos D, Zavos C, Boura P, Konstas AGP, et al. Eradication of *Helicobacter pylori* may be beneficial in the management of chronic open-angle glaucoma. *Arch Intern Med*. 2002 Jun;162(11):1237.
- 83 Chen HY, Lin CL, Chen WC, Kao CH. Does *Helicobacter pylori* eradication reduce the risk of open angle glaucoma in patients with peptic ulcer disease? *Medicine*. 2015 Sep;94(39):e1578.
- 84 Tezel G, Seigel GM, Wax MB. Autoantibodies to small heat shock proteins in glaucoma. *Invest Ophthalmol Vis Sci*. 1998 Nov;39(12):2277–87.
- 85 Tezel G, Wax MB. The mechanisms of hsp27 antibody-mediated apoptosis in retinal neuronal cells. *J Neurosci*. 2000 May;20(10):3552–62.
- 86 Tezel G, Hernandez R, Wax MB. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. *Arch Ophthalmol*. 2000 Apr;118(4):511.
- 87 van Eden W, Jansen MAA, Ludwig I, van Kooten P, van der Zee R, Broere F. The enigma of heat shock proteins in immune tolerance. *Front Immunol*. 2017 Nov;8:1599.
- 88 Chen H, Cho K-S, Vu THK, Shen C-H, Kaur M, Chen G, et al. Commensal microflora-induced T cell responses mediate progressive neurodegeneration in glaucoma. *Nat Commun*. 2018;9(1):3209.
- 89 Su GL, Ko CW, Bercik P, Falck-Ytter Y, Sultan S, Weizman AV, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. *Gastroenterology*. 2020 Aug;159(2):697–705.
- 90 Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. *Genome Med*. 2016 Dec;8(1):52.
- 91 van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med*. 2013 Jan;368(5):407–15.
- 92 Kootte RS, Levin E, Salojärvi J, Smits LP, Hartstra AV, Udayappan SD, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. *Cell Metab*. 2017 Oct;26(4):611–9.e6.
- 93 Duan FF, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. *Diabetes*. 2015 May;64(5):1794–803.
- 94 Górski A, Bollyky PL, Przybylski M, Borysowski J, Międzybrodzki R, Jończyk-Matysiak E, et al. Perspectives of phage therapy in non-bacterial infections. *Front Microbiol*. 2019 Jan;9:3306.
- 95 Ramachandran G, Bikard D. Editing the microbiome the CRISPR way. *Philos Trans R Soc Lond B Biol Sci*. 2019 May;374(1772):20180103.